| Company/Division name | Oxford Biomedica |
| Parent company | Oxford Biomedica Solutions LLC |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 20222 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 130 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Near Boston |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Gene and cell therapy |
